Thank you, Sam. Good morning, I am Mark Chekanow, Director of Investor Relations at SWM. Thank you for joining us to discuss SWM's Fourth Quarter and Full Year 2014 Earnings Results. On today's call, Frédéric will share some high-level comments about our fourth quarter and full year performance, 2015 outlook and strategic priorities; and Steve will provide details on our operations; and Jeff will take you through a detailed review of our financial results and 2015 financial guidance. We'll then take your questions. Before we begin, I would like to remind you that the comments included in today's conference call include forward-looking statements. Actual results may differ materially from the results suggested by these comments for a number of reasons, which are discussed in more detail in our Securities and Exchange Commission Filings, including our quarterly report on Form 10-Q, and our annual report on form 10-K. Certain financial measures discussed during this call exclude restructuring and impairment expenses, results of discontinued operations, noncash amortization expenses, start-up costs of a new mill, accelerated depreciation of assets in Brazil, tax valuation allowances and purchase accounting adjustments and are, therefore, non-GAAP financial measures. Reconciliations of these measures to the closest GAAP measures are included in the appendix of this presentation. I will now turn the call over to Frédéric.
Frédéric P. Villoutreix: Thank you, Mark, and good morning, everyone. Late yesterday, we released our fourth quarter and full year earnings, and this morning we will present our financial results and business updates. I would like to begin the call by quickly reviewing our financial performance and providing some color on the key factors that impacted our results over the course of 2014 and our outlook for 2015. During 2014, we faced some significant headwinds in our tobacco businesses, certainly more than anticipated. However, we slightly exceeded our earnings guidance of $3.40, aided in part by our share buyback. Cash flow remained strong, despite pressure on operating profits, with free cash flow from 2014 finishing at $130 million. In 2014, we returned more than 70% of free cash flow to investors through our steadily increasing dividend and a $15 million share buyback. Our top line reflected the continued challenges in our tobacco end markets, with fourth quarter revenues down 7.5% and full year revenues up only 2.8%, despite the acquisition of DelStar in late 2014. However, as Jeff and Steve will cover, fourth quarter was negatively impacted by foreign currency exchange rates and a short-term labor disruption in France. Adjusted EPS for the fourth quarter of $0.77, was down from $0.91 in the year-ago period, and for the full year was $3.46. 2014 was clearly a challenging year, and while we delivered on plan, our management team was by no means pleased with the overall financial results. Overall, we responded to these challenges, appropriately. We were not as timely as we could have been, regarding several of our restructuring actions. These restructurings began in 2014, and we expect that their financial benefits will be more fully realized in 2015. Top line growth was disappointing in 2014, as the revenue from our DelStar acquisition was largely offset by declines in RTL and tobacco paper volumes, and LIP pricing concessions made in 2015. It is fair to say, however, that while we expected weak RTL volumes and lower LIP pricing, the tobacco paper volume declines were higher than expected. Consequently, as we face lower capacity utilization, we loaded machines with lower value paper products, driving negative mix impacts. This development was the primary reason our operating profits for the Paper segments and the company overall were below our initial expectations for the year. Volume mix and pricing, resulted in Paper segment revenue decline of 8.7% in 2014, well in excess of the 1% of the whole volume decline, with a meaningful variance between volume and revenue performance seen in the latter part of the year. We also continued to take advantage of a strong balance sheet to grow as of yearend, with investments in our RTL joint venture in China as well as targeted investments in paper and filtration. Despite these actions, we expect the continued challenges in the Paper segment, related to smoking attrition and pricing pressure to offset a portion of those efforts. We plan to address these issues for additional capacity rationalizations and restructuring activities. In defense of our LIP technology, we have initiated a patent infringement action against one of our competitors. In addition, the recent weakening of the euro has presented us with a major headwind for 2015. Taking all of these factors into account, our guidance for 2015 adjusted EPS is $3.50, up slightly versus 2014. We note that this guidance assumes a $0.20 negative currency impact, given the recent decline in the euro. While our outlook reflects a stabilization of earnings, we are not satisfied with the modest level of growth built into our 2015 guidance, even when excluding the currency impact. Looking long-term, our strategy remains focused on effectively managing our tobacco businesses, maximizing cash flow for investments and strategic diversification, and creating a more sustainable growth in enterprise over the longer run. The formation of our Filtration Segment has progressed well over the past 12 months, with the integration of DelStar and subsequent leveraging of this platform with 2 acquisitions. We plan to accelerate our efforts to execute on more significant acquisitions, not only in our Filtration segments, but also on value-added diversification associated with our paper business. Importantly, with net debt to adjusted EBITDA at 0.8x and strong cash flows from our existing businesses we remained conservatively levered and prepare for the increased and accelerated investments in both organic growth and acquisition that will be required to execute our strategy. With that context, I will now go into detail on several of our strategic priorities and developments that are key to our long-term plans. The much anticipated commercial launch of our Reconstituted Tobacco JV in China, CTS, occurred during the fourth quarter. While we anticipate quarterly volume lumpiness during 2015, we project CTS to contribute in excess of $5 million of net income or at least $0.16 of EPS in 2015. The expected stabilization of the Recon segments combined with this new CTS volume, leads to forecasted other Recon volume growth of more than 20% in 2015, demonstrating the positive outlook we have for SWM's global Recon operations. We had an exciting fourth quarter in our Filtration segment, executing 2 strategic acquisitions and progressing closer to commercialization of our European expansion. Regarding our acquisitions, each represents an opportunity to significantly expand existing end markets for DelStar. The assets we acquired from Smith & Nephew in the U.K. not only doubled our presence in the medical arena, adding a portfolio of wound management products such as films, foams, nets and tapes, all resin based small goods, but also accelerates DelStar's international expansion into Europe that we have referenced previously. This business complements our existing healthcare product line, which is focused on finger bandages. We believe we can add value by fostering an integrated sales effort with existing DelStar resources and gain benefits of scale and leadership in the specialty product area. The other acquisition was for certain assets of Pronamic Industries and early stage niche producer of air filtration media. Pronamic HVAC products are found in a wide range of residential air filters and high-end commercial applications. We expect this transaction to transform DelStar's small air filtration presence with the addition of new product lines and manufacturing technologies. We are excited about the long-term growth potential of these early stage assets. Combined, these assets we have purchased for approximately $30 million, and I expect it to add more than $35 million in revenue and between $0.08 and $0.10 of EPS this year. Although, the size of these deals was at the lower end of the range of transactions we typically target, the value of purchase price related to EPS accretion is representative of the bolt-on opportunities we anticipated when we acquire DelStar in late 2015. We look forward to integrating these strategic businesses and driving continued growth in our filtration segments. Moving to our LIP franchise and the upcoming South Korean LIP implementation. The continued lack of clarity on technical specifications that will be implemented in Korea and the recent large tax hike on cigarettes give reason for caution regarding expectations. It remains unclear whether international standards or less-strict fire safety performance standards will be mandated in South Korea. The latter, which could open the door for competing products or technologies. The tax increase, which recently raised the price of cigarettes to South Korean consumers by about 80% is currently causing reduced consumption. Based on the current trend of reduced cigarette consumption and the uncertainty around technical LIP standards, we have factored only a nominal benefit for LIP adoption in South Korea into our guidance and can no longer be confident that adoption will offer a meaningful offset to the smoking attrition rates in the U.S. and Europe in 2015. We've been talking for several quarters about the 2014 impact of lower LIP prices, and we have incorporated further price compression in our 2015 outlook. To provide some historical perspective, as a product innovator and technology leader, our LIP products have found a premium versus the industry for several years. As you may remember, we adjusted prices with several key customers in late 2015 to extend their agreements and maintain share, ensuring that SWM remains the leading provider of LIP papers around the world. We note that following the pricing concessions in 2014 and those becoming effective in 2015, which are factored into our outlook of global LIP prices are more in line with our competition now. While we expect long-term pricing on LIP products to be competitive, we believe pressures we will feel in 2016 and beyond will be less pronounced than both seen in 2014 and expected in 2015. Regarding LIP litigation, in order to help protect the substantial investment that we've made over the years in our LIP technology and in terms of property and its economic value to us, in early 2015 we initiated patent infringement litigation in Germany against a competitor not under current -- under a current license agreement with us. The expected impact of such litigation is reflected in our 2015 guidance. We are limited in our ability to provide you any further details on this topic at this time. With respect to our organic diversification efforts, we have taken steps to provide the concentrated focus and leadership needed to both manage our existing nontobacco product lines, and more importantly, accelerate our in-house nontobacco product development and commercialization. I'm convinced that we now have the vision and know how to more extensively apply our paper engineering expertise outside tobacco. To lead this effort, we have added a new executive, with significant experience in diversifying paper products and building new channels for our advanced fibers and materials. A more structured approach should result in a more effective effort to transform our sales composition, as we look to utilize our asset base for higher value-add applications in areas such as consumer products and industrial goods. This area will also be a target for potential acquisitions of value-added and synergistic products. Let me now turn the call over to Steve to discuss operations in more detail.